PharmaTelevision - MolMed’s Key Transplant Mortality Findings

PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: MolMed’s Key Transplant Mortality Findings

Visitors: You are watching a 5 minute preview.

Get more information and subscribe now

RSS

Twitter

In This Episode:

Summary
Transcript
Participants
Company

MolMed’s approach to cancer is based on an integrated strategy that provides both drugs effectively targeting the growing tumour mass in the acute stage, and highly selective therapies to eliminate residual disease.

Dr Fintan Walton talks to Holger Neecke, Director of Business Development and Investor Relations at MolMed, about:

• how the company’s business model changed when Roche acquired Boehringer Mannheim

• how the company’s cell therapy works and how it compares to that of competitors’

• the key phase II findings for the TK cell therapy in relation to transplant mortality

• plans for the future, including those for licensing in the USA and manufacturing in the UK

Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.

Company origin and its focus towards cancer therapeutics

Fintan Walton:

Hello and welcome to PharmaVentures business review here at Bio in Atlanta. On this show I have Holger Neecke who is the Director of Business Development and Investor Relations at a company called MolMed in Milano, Italy. Welcome to the show.

Holger Neecke:

Yeah thank you Fintan Walton for this opportunity.

Fintan Walton:

MolMed is a company that goes back to the Mid 1990's, 1997 when it actually started operating. So it's been around for nearly 12-years now and it's obviously focused in Italy. Could you tell us little bit about the story behind MolMed, how it originated and how it's become the company that is today?

Holger Neecke:

Yeah, MolMedwas originally founded as a joint venture between the German Boehringer Mannheim and San Raffaele Bio Medical Science park in Italy one of the largest research institutions in Italy and in Europe to provide a cell therapy service business to the hospital. When Boehringer Mannheim was acquired by Roche in 1998 the business model changed. Roche was not interested in cell therapies so the equity stake of by Roche was sold to an investment fund, with the entry of this investment fund we changed our business model from a service to a product company and started in-licensing products from the San Raffaele Institute.

Fintan Walton:

Today MolMed is focused on what therapy areas?

Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.

Holger Neecke

Director business development

Holger Neecke joined MolMed in October 2001. Before, he worked at Biopolo Scrl, one of the leading biotechnology transfer agencies in Italy, where he developed and evaluated business plans for start-up companies. At MolMed, he has acquired a broad expertise in biotech business development, particularly by structuring, negotiating and finalizing important license agreements with pharma and biotech companies and institutions in Europe, Japan and the U.S. .Holger Neecke holds a degree in Molecular Biology from the University of Basel, Switzerland, a PhD in Genetics from the University of Milan, and a MBA from SDA Bocconi Business School, Milan.

MolMed

MolMed S.p.A. is a medical biotechnology company focused on discovery, R&D, and clinical validation of innovative therapies for the treatment of cancerformed in 1997 as a joint venture between Boehringer Mannheim and San Raffaele Science Park to provide cell therapy to hospitals. MolMed is located in Milan, Italy, within the San Raffaele Science Park, which includes the renowned research hospital and scientific institute, along with several thriving biotechnology companies, and a private university.